Israel's Purple Biotech Q4 net loss widens on impairment charge

Reuters03-13
Israel's <a href="https://laohu8.com/S/PPBT">Purple Biotech</a> Q4 net loss widens on impairment charge

Overview

  • Israel immunotherapy developer's Q4 net loss widened on a $20.5 mln impairment charge

  • Adjusted operating loss for Q4 increased due to higher CAPTN-3 platform development spending

  • Company ended 2025 with $9.5 mln in cash, providing runway into 2027

Outlook

  • Purple Biotech expects cash position of $9.5 mln to provide funding into 2027

  • Company plans to advance CAPTN-3 program and share additional data during 2026

Result Drivers

  • IMPAIRMENT CHARGE - $20.5 mln impairment loss recognized for CM24 and NT219 programs after decision to pause development pending partnership or funding

  • CAPTN-3 DEVELOPMENT SPENDING - Higher research and development expenses in Q4 driven by CAPTN-3 platform chemistry, manufacturing, and controls activities

Company press release: ID:nGNXm9N1b

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 EPS

$0.10

Q4 Net Income

-$23.6 mln

Q4 Adjusted Operating Income

-$2.9 mln

Q4 Operating Income

-$23.4 mln

Analyst Coverage

  • The one available analyst rating on the shares is "buy"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Purple Biotech Ltd is $340.00, about 8,754.2% above its March 12 closing price of $3.84

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment